Skip to content
20-F

Annual Report (Foreign)

NYMOX PHARMACEUTICAL CORPORATION NYMXF

0001640334-25-000972

← back to feed
Filed
Jun 3, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2024 93.67M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 91.69M sh
Shares Diluted FY 2024 · Dec 31, 2022 89.38M sh
Shares Outstanding FY 2024 · Dec 31, 2024 94.54M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$2.6M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$4.06M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$5.21M
Stockholders Equity FY 2024 · Dec 31, 2024 −$6.78M
Stockholders Equity FY 2024 · Dec 31, 2023 −$3.17M
Stockholders Equity FY 2024 · Dec 31, 2022 −$482K
Stockholders Equity FY 2024 · Dec 31, 2021 −$506K
Current Liabilities FY 2024 · Dec 31, 2024 $7.43M
Current Liabilities FY 2024 · Dec 31, 2023 $3.8M
Total Liabilities FY 2024 · Dec 31, 2024 $7.43M
Total Liabilities FY 2024 · Dec 31, 2023 $3.8M
Current Assets FY 2024 · Dec 31, 2024 $653K
Current Assets FY 2024 · Dec 31, 2023 $625K
Total Assets FY 2024 · Dec 31, 2024 $654K
Total Assets FY 2024 · Dec 31, 2023 $627K
Eps Basic FY 2024 · Dec 31, 2024 −$0.05
Eps Basic FY 2024 · Dec 31, 2023 −$0.10
Eps Basic FY 2024 · Dec 31, 2022 −$0.07
Rd Expense FY 2024 · Dec 31, 2024 $3.28M
Rd Expense FY 2024 · Dec 31, 2023 $3.99M
Rd Expense FY 2024 · Dec 31, 2022 $3.77M
Net Income FY 2024 · Dec 31, 2024 −$4.49M
Net Income FY 2024 · Dec 31, 2023 −$8.84M
Net Income FY 2024 · Dec 31, 2022 −$6.58M
Operating Income FY 2024 · Dec 31, 2024 −$4.28M
Operating Income FY 2024 · Dec 31, 2023 −$8.35M
Operating Income FY 2024 · Dec 31, 2022 −$6.65M
Cost Of Revenue FY 2024 · Dec 31, 2023 $0
Cost Of Revenue FY 2024 · Dec 31, 2022 $0
Revenue FY 2024 · Dec 31, 2023 $0
Revenue FY 2024 · Dec 31, 2022 $0